{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:48:02Z","timestamp":1792025282751,"version":"4.4.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.cllc.2026.09.004","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:29:27Z","timestamp":1789831767000},"page":"25-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of Prognostic Value of CEACAM5 Expression Using Archival Tissue and Real-World Evidence of Metastatic Patients with NSCLC in United States"],"prefix":"10.1016","volume":"27","author":[{"given":"Ashok","family":"Krishna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Lebovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lubwama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"McCracken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manmeet S.","family":"Ahluwalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Seluzhytsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2026.09.004_bib0001","first-page":"146","article-title":"The treatment of metastatic non-small cell lung cancer in a new era of personalized medicine","volume":"5","author":"Vera","year":"2015","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2026.09.004_bib0002","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.cllc.2026.09.004_bib0003","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.cllc.2026.09.004_bib0004","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non\u2013small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.cllc.2026.09.004_bib0005","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/s-0033-1342961","article-title":"Non-small-cell lung cancer: treatment of late stage disease: chemotherapeutics and new frontiers","volume":"30","author":"Scheff","year":"2013","journal-title":"Semin Intervent Radiol"},{"key":"10.1016\/j.cllc.2026.09.004_bib0006","unstructured":"Genentech, Inc. Tecentriq (atezolizumab) injection: prescribing information. South San Francisco, CA: Genentech, Inc.; 2026. Available from: Official prescribing information."},{"issue":"17","key":"10.1016\/j.cllc.2026.09.004_bib0007","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2026.09.004_bib0008","unstructured":"Merck Sharp & Dohme LLC. Keytruda (pembrolizumab) injection: prescribing information. Rahway, NJ: Merck Sharp & Dohme LLC; 2026. Available from: Official prescribing information."},{"key":"10.1016\/j.cllc.2026.09.004_bib0009","unstructured":"Bristol-Myers Squibb Company. Opdivo (nivolumab) injection: prescribing information. Princeton, NJ: Bristol-Myers Squibb Company; 2026. Available from: Official prescribing information."},{"issue":"24","key":"10.1016\/j.cllc.2026.09.004_bib0010","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1158\/1078-0432.CCR-19-4051","article-title":"Preclinical activity of SAR408701: a novel anti-CEACAM5-maytansinoid antibody-drug conjugate for the treatment of CEACAM5-positive epithelial tumors","volume":"26","author":"Decary","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.cllc.2026.09.004_bib0011","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1369\/0022155415609098","article-title":"Identification of CEACAM5 as a biomarker for prewarning and prognosis in gastric cancer","volume":"63","author":"Zhou","year":"2015","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.cllc.2026.09.004_bib0012","doi-asserted-by":"crossref","first-page":"12","DOI":"10.18632\/genesandcancer.230","article-title":"CEACAMS 1, 5, and 6 in disease and cancer: interactions with pathogens","volume":"14","author":"Thomas","year":"2023","journal-title":"Genes Cancer"},{"issue":"3\u20134","key":"10.1016\/j.cllc.2026.09.004_bib0013","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10555-013-9444-6","article-title":"Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis","volume":"32","author":"Beauchemin","year":"2013","journal-title":"Cancer Metastasis Rev"},{"issue":"6","key":"10.1016\/j.cllc.2026.09.004_bib0014","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1007\/s10637-020-00955-w","article-title":"The old CEACAMs find their new role in tumor immunotherapy","volume":"38","author":"Han","year":"2020","journal-title":"Invest New Drugs"},{"issue":"6","key":"10.1016\/j.cllc.2026.09.004_bib0015","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0959-8049(02)00811-0","article-title":"Clinical utility of biochemical markers in colorectal cancer: European group on tumour markers (EGTM) guidelines","volume":"39","author":"Duffy","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2026.09.004_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107356","article-title":"The search for therapeutic targets in lung cancer: preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape","volume":"184","author":"Lefebvre","year":"2023","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.cllc.2026.09.004_bib0017","doi-asserted-by":"crossref","DOI":"10.1177\/0300060520959478","article-title":"CEACAM5 stimulates the progression of non-small-cell lung cancer by promoting cell proliferation and migration","volume":"48","author":"Zhang","year":"2020","journal-title":"J Int Med Res"},{"issue":"3","key":"10.1016\/j.cllc.2026.09.004_bib0018","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1208\/s12248-021-00563-3","article-title":"Clinical pharmacology regulatory sciences in drug development and precision medicine: current status and emerging trends","volume":"23","author":"Liu","year":"2021","journal-title":"AAPS J"},{"issue":"2","key":"10.1016\/j.cllc.2026.09.004_bib0019","article-title":"The landscape of CEACAM5 expression by immunohistochemistry in NSCLC","volume":"7","author":"Hsu","year":"2025","journal-title":"JTO Clin Res Rep"},{"issue":"11","key":"10.1016\/j.cllc.2026.09.004_bib0020","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.21037\/tcr-24-983","article-title":"Sex-based differences in CEACAM5 expression in lung cancer","volume":"13","author":"Woodard","year":"2024","journal-title":"Transl Cancer Res"},{"issue":"1","key":"10.1016\/j.cllc.2026.09.004_bib0021","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/annonc\/mdn538","article-title":"Expression of molecular markers in mediastinal nodes from resected stage I non-small-cell lung cancer (NSCLC): prognostic impact and potential role as markers of occult micrometastases","volume":"20","author":"Benlloch","year":"2009","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2026.09.004_bib0022","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1021\/acs.jproteome.5b00819","article-title":"Quantitative secretomic analysis identifies extracellular protein factors that modulate the metastatic phenotype of non-small cell lung cancer","volume":"15","author":"Hu","year":"2016","journal-title":"J Proteome Res"},{"issue":"10","key":"10.1016\/j.cllc.2026.09.004_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2024.09.443","article-title":"Exploratory analyses of tusamitamab ravtansine vs docetaxel in previously treated non-squamous NSCLC patients: CARMEN-LC03","volume":"19","author":"Cho","year":"2024","journal-title":"J Thorac Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426001221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426001221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:29:00Z","timestamp":1792024140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426001221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1525730426001221"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.09.004","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of Prognostic Value of CEACAM5 Expression Using Archival Tissue and Real-World Evidence of Metastatic Patients with NSCLC in United States","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}